Announcements Trials
Browse Landscape

Phase

Phase NA 8Phase 2 4Phase 1/2 2Phase 1 2

Status

Completed 50Terminated 20Recruiting 9Active not recruiting 8Withdrawn 4Not yet recruiting 3Unknown 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Breast Neoplasms 111Carcinoma, Non-Small-Cell Lung 102Prostatic Neoplasms 66Multiple Myeloma 64Neoplasm Metastasis 63Colorectal Neoplasms 63Neoplasms 59Lung Neoplasms 51Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 41Recurrence 40Lymphoma 40Leukemia, Lymphocytic, Chronic, B-Cell 36Pancreatic Neoplasms 34Melanoma 34Head and Neck Neoplasms 26Glioblastoma 26Rectal Neoplasms 25Ovarian Neoplasms 25Lymphoma, Large B-Cell, Diffuse 25Leukemia 24Brain Neoplasms 24Squamous Cell Carcinoma of Head and Neck 23Hematologic Neoplasms 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Myelodysplastic Syndromes 20Colonic Neoplasms 20Triple Negative Breast Neoplasms 19Lymphoma, Non-Hodgkin 19

Interventions

Petrolatum 2Fluorouracil 2trametinib 1talimogene laherparepvec 1pimonidazole 1fluoromisonidazole 1dabrafenib 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Skin Neoplasms × Clear all
NCT04329221 2025-05-07

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Massachusetts General Hospital

Phase 2 Withdrawn
Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms, Keratosis, Actinic

NCT04642287 2025-05-07

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Massachusetts General Hospital

Phase 2 Withdrawn
Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms, Keratosis, Actinic

NCT03972046 2020-10-19

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

TriHealth Inc.

Phase 2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡